Latest health news and updates
Total: 73
Recordati’s Chinese subsidiary has filed to deregister, ending supply of osilodrostat — the only oral drug for Cushing’s syndrome on the Chinese market — less than a year after its commercial launch. The withdrawal highlights structural problems in China’s rare‑disease market: high prices, thin sales, uncertain reimbursement and weak incentives for suppliers, all of which risk interrupting care for vulnerable patients.
